NCT01829971终止1 期
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 155
- 试验地点
- 10
- 主要终点
- The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)
研究概览
简要总结
This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.
详细描述
This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety, Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in patients with unresectable primary liver cancer or advanced or metastatic cancer with or without liver involvement or hematologic malignancies. MRX34 will be administered daily x 5 with 2 weeks off (total of 21 days) for 3 cycles followed by a no-treatment observation period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥ 18 years
- •Patients with histologically confirmed viral related hepatocellular, SCLC, non-cutaneous/ non-uveal melanoma, ovarian, TNBC, Sarcoma, Bladder and RCC.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- •Acceptable liver function:
- •Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); for patients with hepatocellular carcinoma only, total bilirubin ≤ 3 mg/dL (i.e. Child-Pugh Score for bilirubin is no greater than 2).
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 5 x ULN.
- •Acceptable renal function:
- •Serum creatinine ≤ 1.5 times the ULN, or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above 1.5 times the institutional normal
- •Acceptable hematological status:
- •Absolute Neutrophil Count (ANC) ≥ 1500 cells/mm3
- •Platelet count ≥ 100,000 plts/mm3 (without transfusion); ≥ 75,000 plts/mm3 for patients with hepatocellular carcinoma only. For hematologic malignancy patients blood counts cited above do not apply
- •Hemoglobin ≥ 9 g/dL
- •For the hematologic malignancy patients, blood count values cited above do not apply.
- •Prothrombin time (PT) or International Normalized Ratio (INR) ≤ 1.25 x ULN; for patients with hepatocellular carcinoma only, INR <1.7 or prothrombin time (PT) or < 4 seconds above ULN (i.e. Child-Pugh Score is no greater than 1 for the coagulation parameter); for patients with hepatocellular carcinoma only, serum albumin > 2.8 g/dL (i.e. Child-Pugh Score for albumin is no greater than 2). For the hematologic malignancy patients, the coagulation and albumin status cited above do not apply
- •For patients with hepatocellular carcinoma only, Child-Pugh Class A (score 5-6) disease. Score for hepatic encephalopathy must be 1; the score for ascites must be no greater than 2 and clinically irrelevant; for the determination of the Child-Pugh Class.
排除标准
- •Myocardial infarction within the past 6 months, unstable and/or symptomatic arrhythmia, or evidence of ischemia on ECG.
- •Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
- •Pregnant or nursing women.
- •Known infection with human immunodeficiency virus (HIV).
- •Serious nonmalignant disease (e.g., hydronephrosis, liver failure, heart failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.
- •Patients with recent history of hemorrhage and patients predisposed to hemorrhage due to coagulopathies or structural anomalies.
- •Patients who require treatment with therapeutic doses of coumadin-type anticoagulants (maximum daily dose of 1mg allowed for port line patency permitted).
- •Patients with cirrhosis classed as Child-Pugh B or C.
- •Patients with central nervous system (CNS) metastasis. Intrathecal chemotherapy is allowed for patients who require CNS prophylaxis or therapy.
- •Patients for whom dexamethasone is contraindicated.
研究组 & 干预措施
MRX34
Experimental
Single agent MRX34
干预措施: MRX34 (Drug)
结局指标
主要结局
The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)
时间窗: 18 months
Dose-limiting toxicity (DLT) in 3-6 patients at the end of one treatment cycle
次要结局
- Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing(18 months)
- Number of patients with evidence of clinical activity of MRX34(18 months)
研究者
研究点 (10)
Loading locations...
相似试验
终止
1 期
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersKRAS Mutation-Related TumorsColorectal CancerPancreatic CancerNon-small Cell Lung CancerNCT04916236The Netherlands Cancer Institute24
已完成
2 期
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria2023-506963-32-00Moderna Therapeutics Inc.16
已完成
不适用
Studying Biomarkers in Cell Samples From Patients With Acute Myeloid LeukemiaLeukemiaNCT01057199Children's Oncology Group6
招募中
1 期
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerAdvanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8NCT04762199Emory University69
撤回
1 期
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Relapsed or Refractory Multiple MyelomaNCT05918250ModernaTX, Inc.